The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”
Open accessAbstract
// Marco Fiorillo 1,2,3 , Andrea F. Verre 4 , Maria Iliut 4 , Maria Peiris-Pag é s 1,2 , Bela Ozsvari 1,2 , Ricardo Gandara 1,2 , Anna Rita Cappello 3 , Federica Sotgia 1,2 , Aravind Vijayaraghavan 4 and Michael P. Lisanti 1,2 1 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK 2 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK 3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Italy 4 School of Materials and National Graphene Institute, University of Manchester, UK Correspondence: Michael P. Lisanti, email: // Aravind Vijayaraghavan, email: // Keywords : nanomaterials, graphene oxide, cancer stem cells, multiple cancer types: breast, ovarian Received : January 01, 2015 Accepted : February 12, 2015 Published : February 24, 2015 Abstract Tumor-initiating cells (TICs), a.k.a. cancer stem cells (CSCs), are difficult to eradicate with conventional approaches to cancer treatment, such as chemo-therapy and radiation. As a consequence, the survival of residual CSCs is thought to drive the onset of tumor recurrence, distant metastasis, and drug-resistance, which is a significant clinical problem for the effective treatment of cancer. Thus, novel approaches to cancer therapy are needed urgently, to address this clinical need. Towards this end, here we have investigated the therapeutic potential of graphene oxide to target cancer stem cells. Graphene and its derivatives are well-known, relatively inert and potentially non-toxic nano-materials that form stable dispersions in a variety of solvents. Here, we show that graphene oxide (of both big and small flake sizes) can be used to selectively inhibit the proliferative expansion of cancer stem cells, across multiple tumor types. For this purpose, we employed the tumor-sphere assay, which functionally measures the clonal expansion of single cancer stem cells under anchorage-independent conditions. More specifically, we show that graphene oxide effectively inhibits tumor-sphere formation in multiple cell lines, across 6 different cancer types, including breast, ovarian, prostate, lung and pancreatic cancers, as well as glioblastoma (brain). In striking contrast, graphene oxide is non-toxic for “bulk” cancer cells (non-stem) and normal fibroblasts. Mechanistically, we present evidence that GO exerts its striking effects on CSCs by inhibiting several key signal transduction pathways (WNT, Notch and STAT-signaling) and thereby inducing CSC differentiation. Thus, graphene oxide may be an effective non-toxic therapeutic strategy for the eradication of cancer stem cells, via differentiation-based nano-therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemistry of graphene oxide
Dreyer, D. R., Park, S., Bielawski, C. W., & Ruoff, R. S. (2010) · Chem. Soc. Rev. · doi:10.1039/b917103g · Cited by 11,653
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Cited by
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy
Qin, W., Huang, G., Chen, Z., & Zhang, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00001 · Cited by 656
Graphene and graphene oxide as nanomaterials for medicine and biology application
Priyadarsini, S., Mohanty, S., Mukherjee, S., Basu, S., & Mishra, M. (2018) · Journal of Nanostructure in Chemistry · doi:10.1007/s40097-018-0265-6 · Cited by 570
Assessing biocompatibility of graphene oxide-based nanocarriers: A review
Kiew, S. F., Kiew, L. V., Lee, H. B., Imae, T., & Chung, L. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.015 · Cited by 301
Metadata
- Authors
- Fiorillo, M., Verre, A. F., Iliut, M., Peiris-Pagés, M., Ozsvari, B., Gandara, R., Cappello, A. R., Sotgia, F., Vijayaraghavan, A., & Lisanti, M. P.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-02-24
- Volume
- 6
- Issue
- 6
- Pages
- 3553-3562
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1546117988
- Cited by
- 234
- References
- 2
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.